why choose us

First received: September 01, 2023

Clinical Trial: Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

Study Status: NOT_YET_RECRUITING

Recruit Status: NOT_YET_RECRUITING

Condition: Metastatic Castration-resistant Prostate Cancer

Study Type: INTERVENTIONAL


Official Title: A Phase II Study of Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

Brief Summary: The goal of this clinical trial is to test the anti-tumor activity of bortezomib in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC) with PTEN Deletion.The main question[s] it aims to answer is if the use of bortezomib will result in a decline in PSA for participants.Participants will receive a sub-cutaneous injection of bortezomib for up 8 cycles.Each cycle is about 21 days.

Read more